Eager to offset headwinds tied to patent expiration on its best-selling Advair, GlaxoSmithKline(NYSE:GSK) is investing $300 million in DNA-sequencing company 23andMe. Can insight from 23andMe's millions of customers help GlaxoSmithKline create better medicine?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,